Public Companies
Christian Angermayer Gives Insight on Future of Atai’s Ketamine Program
Christain Angermayer gave some clarification on PCN-101, atai’s ketamine program, hinting at new direction for the compound.
The post Christian Angermayer…
“atai’s management believes these data support the concept of at-home use of PCN-101 in future studies.” – Christian Angermayer
Yesterday we reported on results from atai’s new Phase 1 study of its PCN-101 ketamine compound. The drug had disappointing trial results back in January and the company has been researching where to go next with one of its (formerly?) most promising drugs.
atai announced results from Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The Phase 1 study looked at PCN-101 delivered subcutaneously compared to PCN-101 delivered intravenously (the previous trial with lackluster results was done intravenously).
Results were promising, showing that subcutaneous injection (directly into the body, like an injection into the arm) could have more efficient results than IV delivery.
But what do these early results mean for the PCN-101 program? This is what ATAI investors have been wondering since January.
atai founder Christain Angermayer gave some clarification on this, giving hope that PCN-101 could be revived as an at-home alternative to Spravato.
Will atai now invest in new trials? Go the partnership route?
See his full comments below.
After some setbacks for @atai_life's R-Ketamine (PCN-101) earlier this year, I am very happy to see good news today.
Some background: We know that Ketamine works for depression. The approval of J&J’s Spravato/S-Ketamine and a growing market for Ketamine clinics (using both…
— Christian Angermayer (@C_Angermayer) August 9, 2023
The post Christian Angermayer Gives Insight on Future of Atai’s Ketamine Program appeared first on Microdose.
ketamine depression investors invest atai-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psychedelics1 week ago
The Onion Pokes Fun at Psychedelics
-
Psilocybin1 week ago
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic